Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea
The regulator approved the drug for moderate to severe obstructive sleep apnea in adults with obesity, the company said. "Too ...
EconoTimes1h
Eli Lilly’s Zepbound Becomes FDA’s First Weight-Loss Drug Approved for Sleep Apnea Treatment
The FDA has approved Eli Lillys Zepbound as the first weight-loss drug to treat obstructive sleep apnea, reshaping care for ...
Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar.
Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug ...
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...
24/7 Wall St2h
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
F.D.A. Approves Weight Loss Drug to Treat Obstructive Sleep Apnea
Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...
24/7 Wall St2h
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 471.82% and ...
Monthly Prescribing Reference2h
FDA Says Shortage of GLP-1 Tirzepatide Is Over
Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss).
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
Premarket movers: FedEx, Eli Lilly, Nike
FedEx Corp shares increased 9% in Friday's premarket session after the package delivery company outlined plans to spin off its FedEx Freight trucking business Eli Lilly s ...
Becker's Hospital Review3h
FDA: No more need for compounded versions of Mounjaro, Zepbound
The FDA has declared the end of the two-year shortages of Eli Lilly's Mounjaro and Zepbound — used to treat diabetes and weight loss, respectively — and has reaffirmed its decision to halt the ...